Business Context and Reporting Period
Pavmed Inc. (PAVM) filed a Form 8-K on March 7, 2024, reporting a significant corporate governance event. The company is incorporated in Delaware and its principal executive offices are located in New York, New York. The filing addresses a notice received from The Nasdaq Stock Market regarding compliance with listing standards.
Key Financial Metrics
This filing does not contain standard financial performance data such as revenue, profit, cash flow, or debt levels. The only financial metric disclosed is the Market Value of Listed Securities (MVLS).
- Market Value of Listed Securities (MVLS): Below $35 million for the last 30 consecutive business days through March 6, 2024.
- Required Minimum MVLS: $35 million under Nasdaq Listing Rule 5550(b)(2).
Material Changes
The material change reported is the failure to maintain the minimum market value requirement for continued listing on the Nasdaq Capital Market. This is a non-financial operational change triggered by the company's stock price performance over the preceding 30-day period.
Outlook, Risks, and Management Commentary
Compliance Timeline: The company has been granted 180 calendar days, until September 3, 2024, to regain compliance.
Compliance Requirement: To avoid delisting, the MVLS must close at $35 million or more for a minimum of ten consecutive business days within the 180-day period.
Current Status: The notice has no immediate effect on trading. Common stock (PAVM) and Series Z warrants (PAVMZ) will continue to trade uninterrupted on The Nasdaq Stock Market LLC.
Management Action: The company intends to consider all available options to regain compliance with Nasdaq listing standards.
Risks: If the company fails to regain compliance by the September 3, 2024 deadline, its securities will be subject to delisting.
Investor Verification Checklist
- Verify the current market capitalization and daily trading volume of PAVM to assess the feasibility of reaching the $35 million MVLS threshold.
- Monitor subsequent filings for any capital raising activities (e.g., reverse stock splits, equity offerings) intended to address the listing deficiency.
- Confirm the status of the Series Z warrants (PAVMZ) and their impact on the total MVLS calculation.
- Review the company's cash position in other filings (10-K/10-Q) to determine if liquidity constraints are contributing to the low market valuation.